Abstracts tagged "Biomarkers"

Abstract Number: 1575 • 2015 ACR/ARHP Annual Meeting
Serum Vascular Cell Adhesion Molecule-1 (VCAM-1) Levels Are Associated with Vascular Dysfunction and Increased Cardiovascular Risk in an Animal Model and Patients with Rheumatoid Arthritis
Ruth Davies¹, Daniela Iacono², Lauren A. Jordan¹, Jessica O Williams¹, Charlotte Rawlings¹, Derek Lang³, Anwen S. Williams¹ and Ernest H. Choy¹, ¹Cardiff University, Institute of Infection and Immunity, Tenovus Building, University Hospital of Wales, Cardiff, United Kingdom, ²Department of Clinical and Experimental Medicine. Rheumatology Section. Second University of Naples, Naples, Italy, ³Institute of Molecular and Experimental Medicine, Cardiff University School of Medicine, Cardiff, United Kingdom
Background/Purpose: Mortality is increased in Rheumatoid arthritis (RA) patients mainly due to cardiovascular (CV) disease; however the biologic mechanisms are unknown. Increased CV risk in…
Abstract Number: 1917 • 2015 ACR/ARHP Annual Meeting
Developing and Validating a Serum Biomarker for the Extent of Skin Disease in Patients with Diffuse Cutaneous Systemic Sclerosis
Lisa Rice¹, Julio Mantero², Giuseppina Stifano¹, Jessica Ziemek³, Robyn T. Domsic⁴ and Robert Lafyatis¹, ¹Boston University School of Medicine, Boston, MA, ²Rheumatology, Boston University School of Medicine, Boston, MA, ³Rheumatology/Arthritis Center, Boston University School of Medicine, Boston, MA, ⁴Medicine - Rheumatology, University of Pittsburgh, Pittsburgh, PA
Background/Purpose: In this study we aimed to both agonistically investigate alterations in the serum proteome of patients with diffuse cutaneous systemic sclerosis (dcSSc), as well…
Abstract Number: 2584 • 2015 ACR/ARHP Annual Meeting
Prediction of Disease Relapses By Multi-Biomarker Disease Test Activity in Rheumatoid Arthritis Patients Tapering DMARD Treatment
Juergen Rech¹, Axel J. Hueber², Matthias Englbrecht², Stephanie Finzel³, Judith Haschka^4,5, Bernhard Manger², Arnd Kleyer³, Michaela Reiser³, Hans-Peter Tony⁶, Stefan Kleinert⁷, Martin Feuchtenberger⁸, Martin Fleck⁹, Karin Manger¹⁰, Wolfgang Ochs¹¹, Matthias Schmitt-Haendle¹², Joerg Wendler¹³, Florian Schuch¹³, Monika Ronneberger¹³, Hanns-Martin Lorenz¹⁴, Hubert Nüßlein¹⁵, Rieke Alten¹⁶, Jayme Fogagnolo Cobra¹⁷, Joerg C. Henes¹⁸, Klaus Krüger¹⁹ and Georg A. Schett²⁰, ¹medical clinic 3, University of Erlangen-Nuremberg, Erlangen, Germany, ²Department of Internal Medicine 3, Rheumatology & Immunology, University of Erlangen-Nuremberg, Erlangen, Germany, ³Department of Internal Medicine 3, University of Erlangen-Nuremberg, Erlangen, Germany, ⁴Medical Department 3, Rheumatology & Immunology, University of Erlangen-Nuremberg, Erlangen, Germany, ⁵Medical Department II, Medical University of Vienna, St. Vincent Hospital Vienna,, Vienna, Austria, ⁶University Hospital Würzburg, Würzburg, Germany, ⁷Rheumatologische Schwerpunktpraxis Erlangen, Erlangen, Germany, ⁸Rheumatologie/Klinische Immunologie, Kreiskliniken Altötting-Burghausen, Burghausen, Germany, ⁹Department of Internal Medicine I, University of Regensburg, 93042 Regensburg, Germany, ¹⁰Rheumatology Practice Bamberg, Bamberg, Germany, ¹¹Rheumatologist in Private Practice, Bayreuth, Germany, ¹²Rheumatology Practice, Bayreuth, Germany, ¹³Schwerpunktpraxis Rheumatologie, Erlangen, Germany, ¹⁴University Hospital Heidelberg, Heidelberg, Germany, ¹⁵University Erlangen, Nürnberg, Germany, ¹⁶Internal Medicine, Rheumatology & Clinical Immunology, Schlosspark-Klinik, University Medicine Berlin, Berlin, Germany, ¹⁷Instituto de Reumatologia de Sao Paolo, Sao Paolo, Brazil, ¹⁸Department of Internal Medicine II, Rheumatology Division, University Hospital Tuebingen, Tuebingen, Germany, ¹⁹Praxiszentrum St. Bonifatius, München, Germany, ²⁰University of Erlangen-Nuremberg, Erlangen, Germany
Background/Purpose: To analyze the role of multi-biomarker disease activity (MBDA) in predicting disease relapses in rheumatoid arthritis (RA) patients in sustained remission, tapering disease modifying…
Abstract Number: 2965 • 2015 ACR/ARHP Annual Meeting
Might Troponin be a Marker for Subclinical Scleroderma Heart Involvement (SHI)?
Chiara Stagnaro¹, Anna d'Ascanio¹, Alice Parma², Umberto Conti³, Michele Emdin⁴, Alessandra Della Rossa¹ and Marta Mosca¹, ¹Internal Medicine, University of Pisa, Pisa, Italy, ²University of Pisa, Pisa, Italy, ³Cardiotoracico, Cardiologia 2, Pisa, Italy, ⁴Fondazione Toscana Gabriele Monasterio, UOC Cardiologia e Medicina Cardiovascolare, Pisa, Italy
Background/Purpose: Systemic sclerosis (SSc) is a rare connective tissue disease with pronounced alterations of the microvascular system, frequent cellular and humoral immunity abnormalities and fibroblast…
Abstract Number: 171 • 2015 ACR/ARHP Annual Meeting
Serum Calprotectin Levels Correlate with Ultrasonographic Synovitis in Rheumatoid Arthritis Patients
Jana Hurnakova¹, Jakub Zavada¹, Petra Hanova¹, Hana Hulejová¹, Martin Klein¹, Herman F Mann¹, Olga Sleglova¹, Marta Olejarova¹, Šárka Forejtová¹, Olga Ruzickova¹, Martin Komarc², Jiri Vencovsky¹, Karel Pavelka¹ and Ladislav Senolt¹, ¹Institute of Rheumatology and Department of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic, Prague, Czech Republic, ²Institute of Biophysics and Informatics of the First Faculty of Medicine, Charles University, Prague, Czech Republic
Background/Purpose: Calprotectin (S100A8/9, MRP8/14) has been demonstrated as a promising biomarker of clinical and laboratory disease activity in rheumatoid arthritis (RA). In addition, two small…
Abstract Number: 583 • 2015 ACR/ARHP Annual Meeting
A Serological Biomarker of Active MMP3, but Total MMP3, Can Early Assess Treatment Efficacy and Differentiate Doses of Tocilizumab and an Early Change in Active MMP3, but Not Total MMP3, Is Associated with Radiographic Change at 1 Year
Anne Sofie Siebuhr¹, Stephanie Nina Kehlet², Kishwar Musa², Inger Byrjalsen³, Morten Asser Karsdal⁴ and Anne C. Bay-Jensen⁵, ¹Rheumatology, Nordic Bioscience, Biomarkers and Research, Herlev, Denmark, ²Laboratory, Nordic Bioscience, Herlev, Denmark, ³Research & Development, Nordic Bioscience, Herlev, Denmark, ⁴Biomarkers and Research, Nordic Bioscience, Herlev, Denmark, ⁵Biomarkers and Research, Rheumatology, Nordic Bioscience, Herlev, Denmark
Background/Purpose: Protease activity, especially MMP3, is known to be increased with arthritis, such as rheumatoid arthritis. MMP3 is mainly expressed by fibroblasts; a key cell…
Abstract Number: 1023 • 2015 ACR/ARHP Annual Meeting
Tumor Necrosis Factor-a (TNF-a) and Interferon Gamma Inducible Protein-10 (IP-10) As Predictors of Active Disease Status in Localized Scleroderma
Kathryn S. Torok¹, Jonathan Yabes², Qi Mi³, Christina Kelsey¹ and Kelsey Magee⁴, ¹Pediatric Rheumatology, Univ of Pittsburgh Med Ctr, Pittsburgh, PA, ²Department of Medicine, University of Pittsburgh, Pittsburgh, PA, ³Department of Sports Medicine and Nutrition, University of Pittsburgh, Pittsburgh, PA, ⁴Pediatrics, University of Pittsburgh, Pittsburgh, PA
Background/Purpose: Localized scleroderma has both inflammatory and fibrotic components contributing to its effect on the skin and underlying tissue. The extent and duration of…
Abstract Number: 1579 • 2015 ACR/ARHP Annual Meeting
Association of Myocardial Abnormalities with N-Terminal Pro-Brain Natriuretic Peptide and Disease Activity in Rheumatoid Arthritis without Cardiac Symptoms, Assessed By Cardiac Magnetic Resonance Imaging
Hitomi Kobayashi¹, Yasuyuki Kobayashi², Isamu Yokoe³, Natsumi Ikumi^4,5, Hirotake Inomata⁶, Atsuma Nishiwaki⁶, Noboru Kitamura¹, Kaita Sugiyama⁶, Hidetake Shiraiwa⁶, Masataka Nozaki⁶, Yosuke Nagasawa⁶, Yoshihiro Matsukawa⁵ and Masami Takei¹, ¹Division of Hematology and Rheumatology, Nihon University School of Medicine, Tokyo, Japan, ²Advanced Biomedical Imaging Informatics, St.Marianna University School of Medicine, Kawasaki, Japan, ³Rheumatology, Itabashi Chuo Medical Center, Tokyo, Japan, ⁴Nihon University School of Medicine, Shinjuku, Japan, ⁵Division of Heamatology and Rheumatology, Nihon University School of Medicine, Tokyo, Japan, ⁶Nihon University School of Medicine, Tokyo, Japan
Background/Purpose: Rheumatoid arthritis (RA) is a multi-organ inflammatory disorder associated with high cardiovascular morbidity and mortality. Cardiac involvements are typically clinically silent, only manifesting as…
Abstract Number: 1936 • 2015 ACR/ARHP Annual Meeting
STAT3-Regulated Gene Expression in Circulating CD4+ T Cells Discriminates RA Patients Independently of Clinical Parameters in Early Arthritis: A Validation Study
Arthur G Pratt¹, Amy E. Anderson¹, Dennis W Lendrem², Andrew Skelton², Jonathan Massey³, Nisha Nair³, Julie Diboll², Ben Hargreaves², Philip M Brown², Anne Barton^4,5 and John D Isaacs², ¹Institute of Cellular Medicine (Musculoskeletal Research Group), National Institute for Health Research Newcastle Biomedical Research Centre based at Newcastle Hospitals Foundation Trust and Newcastle University, Newcastle upon Tyne, United Kingdom, ²Institute of Cellular Medicine (Musculoskeletal Research Group), NIHR Newcastle Biomedical Research Centre, Newcastle Hospitals Foundation Trust and Newcastle University, Newcastle upon Tyne, United Kingdom, ³NIHR Manchester Musculoskeletal Biomedical Research Unit, Manchester Academy of Health Sciences, Manchester, United Kingdom, ⁴NIHR Manchester Musculoskeletal Biomedical Research Unit, Manchester Academic Health Science Centre, Manchester, United Kingdom, ⁵Arthritis Research UK Centre for Genetics and Genomics, University of Manchester, Manchester, United Kingdom
Background/Purpose: A previously described transcriptional signature present in circulating CD4+ T cells of early rheumatoid arthritis (RA) patients implicated STAT3 signalling as an early pathophysiological…
Abstract Number: 2594 • 2015 ACR/ARHP Annual Meeting
Multi-Biomarker Disease Activity Score As a Predictor of Flare in Patients with Rheumatoid Arthritis Who Stop TNF-Alpha-Inhibitor Therapy
Femke Lamers-Karnebeek¹, Marjan Ghiti Moghadam², Harald E. Vonkeman³, Janneke Tekstra⁴, Annemarie Schilder⁵, Henk Visser⁶, Peter M. ten Klooster⁷, Eric H. Sasso⁸, David Chernoff⁹, Willem Lems¹⁰, Dirkjan van Schaardenburg¹¹, Robert Landewé¹², Iet Van Albada¹³, T.R.D.J. Radstake¹⁴, Piet van Riel¹⁵, Mart A.F.J. van de Laar¹⁶ and Tim Jansen¹⁷, ¹Rheumatology, Radboudumc, Nijmegen, Netherlands, ²rheumatology, Medisch Spectrum Twente - Arthritis Center Twente, Enschede, Netherlands, ³Ariensplein 1, Medisch Spectrum Twente - Arthritis Center Twente, Enschede, Netherlands, ⁴Dept. Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands, ⁵Rheumatology, Medisch Centrum Leeuwarden, Leeuwarden, Netherlands, ⁶Rheumatology, Alysis Care Group, Arnhem, Netherlands, ⁷Pcgr, University of Twente, Enschede, Netherlands, ⁸Crescendo Bioscience Inc., South San Francisco, CA, ⁹Crescendo Bioscience, Inc., South San Francisco, CA, ¹⁰Amsterdam Rheumatology and immunology Center, location VU University Medical Center, Department of Rheumatology, Amsterdam, Netherlands, ¹¹Rheumatology, Amsterdam Rheumatology and immunology Center, Academic Medical Center, Amsterdam, Netherlands, ¹²Department of Rheumatology, Amsterdam Rheumatology Center, Amsterdam, The Netherlands, Amsterdam, Netherlands, ¹³Meander MC, Amersfoort, Netherlands, ¹⁴Laboratory for Translational Immunology, University Medical Center Utrecht, Utrecht, Netherlands, ¹⁵Rheumatology, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, ¹⁶Rheumatology, Medisch Spectrum Twente - Arthritis Center Twente, Enschede, Netherlands, ¹⁷VieCuri Medical Center, Venlo, Netherlands
Background/Purpose: Prediction which rheumatoid arthritis (RA) patients in low disease activity (LDA) can successfully discontinue TNF inhibition (TNFi) may improve the cost-effectiveness of RA management.…
Abstract Number: 2984 • 2015 ACR/ARHP Annual Meeting
Scleroderma Bronchoalveolar Lavage Fluid Thrombin Activity: Correlation with Pulmonary Function
Merrideth Ashley Morris¹, Tanjina Akter², Paul Nietert³, Galina S. Bogatkevich² and Richard Silver⁴, ¹Medical University of South Carolina, Charleston, SC, ²Division of Rheumatology & Immunology, Medical University of South Carolina, Charleston, SC, ³Division of Public Health Science, Medical University of South Carolina, Charleston, SC, ⁴Division of Rheumatology and Immunology, Medical University of South Carolina, Charleston, SC
Background/Purpose: Multiple lines of evidence identify thrombin as an important mediator of lung fibrosis in systemic sclerosis (SSc). In addition to demonstrating dramatically high levels…
Abstract Number: 189 • 2015 ACR/ARHP Annual Meeting
Indocyanine Green (ICG) -Enhanced Fluorescence Optical Imaging (FOI) in Patients with Active Rheumatoid Arthritis; A Comparative Study with Ultrasound and Association with Biomarkers
Shin-ya Kawashiri^1,2, Ayako Nishino³, Masataka Umeda³, Shoichi Fukui¹, Yoshikazu Nakashima³, Naoki Iwamoto¹, Kunihiro Ichinose¹, Hideki Nakamura¹, Tomoki Origuchi⁴, Kiyoshi Aoyagi² and Atsushi Kawakami³, ¹Department of Immunology and Rheumatology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan, ²Department of Public Health, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan, ³Department of Immunology and Rheumatology, Nagasaki University, Nagasaki, Japan, ⁴Department of Health Sciences, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan
Methods: Twenty-five active RA patients (mean disease durations 7.5 years and DAS28-ESR 5.90) who fulfilled 2010 RA classification criteria were consecutively enrolled in this study.…
Abstract Number: 595 • 2015 ACR/ARHP Annual Meeting
Discovery of Serum Protein Biomarkers of Response to Adalimumab in Rheumatoid Arthritis and Their Relationship to Biomarkers of Response to Infliximab
Ignacio Ortea¹, Bernd Roschitzki², Eva Tomero³, Juan G. Ovalles-Bonilla⁴, Javier Lopez-Longo⁵, Inmaculada de la Torre⁵, Isidoro Gonzalez-Alvaro⁶, Juan J Gomez-Reino⁷ and Antonio Gonzalez⁸, ¹Maimónides Health Research Institute (IMIBIC), Cordoba, Spain, ²Functional Genomics Center Zurich, University and ETH Zurich, Zurich, Switzerland, ³Rheumatology, Hospital Universitario de La Princesa. IIS La Princesa, Madrid, Spain, ⁴Rheumatology, Hospital General Universitario Gregorio Marañón, Madrid, Spain, ⁵Gregorio Marañon Hospital, Madrid, Spain, ⁶Hospital Univ. de La Princesa, IIS Princesa, Madrid, Spain, ⁷Instituto Investigacion Sanitaria- Hospital Clinico Universitario de Santiago, Santiago de Compostela, Spain, ⁸Laboratorio Investigacion 10 and Rheumatology Unit, Instituto Investigacion Sanitaria- Hospital Clinico Universitario de Santiago, Santiago de Compostela, Spain
Background/Purpose: Biomarkers of response to treatment in rheumatoid arthritis (RA) are sorely needed given the large inter-individual variability in efficacy of the available drugs. However,…
Abstract Number: 1051 • 2015 ACR/ARHP Annual Meeting
Serum Calprotectin As Biomarker of Carotid Atherosclerosis in Patients with Primary Sjögren’s Syndrome
Gabriela Moreira Balarini¹, Eliana Zandonade², leandro tanure³, gilda Aparecida ferreira³, Wildner Mardegan Sardenberg⁴, Érica Vieira Serrano⁴, Cléia Coelho Dias⁵, Túlio Pinho Navarro³, João Felipe Tonini⁴, Hilde H Nordal⁶, Piotr Mydel⁷, Johan Gorgas Brun⁸, Karl Albert Brokstad⁹, Eva Gerdts⁸, Roland Jonsson^10,11 and Valeria Valim^4,12, ¹Department of Medical Clinic, Federal University of Espírito Santo (UFES), Brazil., cachoeiro de itapemirim, Brazil, ²Department of Statistic, Federal University of Espírito Santo (UFES), Brazil., vitória, Brazil, ³Department of Locomotor System, Federal University of Minas Gerais, Brazil., belo horizonte, Brazil, ⁴Department of Medical Clinic, Federal University of Espírito Santo (UFES), Brazil., vitória, Brazil, ⁵Department of Medical Clinic, Federal University of Espírito Santo (UFES), Brazil., vila velha, Brazil, ⁶Broegelmann Research Laboratory/University of Bergen, Norway, bergen, Norway, ⁷Clinical Science, Broegelmann Research Laboratory, Bergen, Norway, ⁸Department of Clinical Science, University of Bergen, Norway, bergen, Norway, ⁹Department of Clinical Science, University of Bergen, Norway., bergen, Norway, ¹⁰Broegelmann Research Laboratory, Department of Clinical Science, University of Bergen, Bergen, Norway, ¹¹Broegelmann research laboratory, Bergen, Norway, ¹²Rheumatology, Universidade Federal do Espírito Santo, Vitória, Brazil
Background/Purpose: The relationship between atherosclerosis, traditional risk factors, disease activity and biomarkers is not well explored. We aimed to identify the association of carotid atherosclerosis…
Abstract Number: 1656 • 2015 ACR/ARHP Annual Meeting
Repeated CD4+ T-Cell Depletion in Patients with Rheumatoid Arthritis over Multiple Cycles of Rituximab Treatment
Matthieu Lavielle¹, Denis Mulleman¹, Hsueh Cheng Sung², Clément Bahuaud², Philippe Goupille¹, Hervé Watier³ and Gilles Thibault³, ¹Service de Rhumatologie, CHRU de Tours, Université François-Rabelais de Tours, CNRS 7292, Tours, France, ²Université François-Rabelais de Tours, CNRS 7292, Tours, France, ³Laboratoire d'Immunologie, CHRU de Tours, Université François-Rabelais de Tours, CNRS 7292, Tours, France
Background/Purpose: CD4+ T-cell depletion after a first cycle of rituximab (RTX) in patients with rheumatoid arthritis (RA) was previously reported by our group (Mélet J…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].